Table 3.
Comparison within centre allocation subgroups of teams performing more than 7% centre allocation transplants and those performing fewer than 7% centre allocation transplants.
| Group 1 centre allocation (n = 236) |
Group 2 centre allocation (n = 100) |
p value | Effect size | |
|---|---|---|---|---|
| Gender (female) | 44 (18.64%) | 16 (16%) | 0.672 | 0.023 |
| Re-transplantation | 2 (0.85%) | 4 (4%) | 0.067 | 0.084 |
| MELD exception | 17 (7.2%) | 7 (7%) | 1 | <0.001 |
| Status at transplant | 0.089 | 0.084 | ||
| Home | 209 (88.56%) | 90 (90%) | ||
| Hospital | 23 (9.75%) | 5 (5%) | ||
| Intensive care unit | 4 (1.69%) | 5 (5%) | ||
| Diabetes | 65 (27.54%) | 28 (28%) | 1 | <0.001 |
| On dialysis | 0 (0%) | 0 (0%) | – | – |
| Hepatocellular carcinoma | 161 (68.22%) | 62 (63%) | 0.423 | 0.044 |
| Decompensated cirrhosis | 41 (17.37%) | 17 (17%) | 1 | <0.001 |
| Hepatic disease no cirrhotic | 3 (1.27%) | 1 (1%) | 1 | <0.001 |
| Encephalopathy | 40 (16.95%) | 22 (22%) | 0.349 | 0.051 |
| Ascites | 104 (44.07%) | 47 (47%) | 0.708 | 0.02 |
| ABO compatibility | 0.026 | 0.097 | ||
| Compatible | 2 (0.85%) | 5 (5%) | ||
| Identical | 233 (98.73%) | 95 (95%) | ||
| Incompatible | 1 (0.42%) | – | ||
| Model for end-stage liver disease | 12.78 (5.44), 12 | 13.14 (6.48), 12 | 0.913 | <0.001 |
| Age | 56.83 (7.66), 57.94 | 56.87 (8.67), 58 | 0.687 | <0.001 |
| BMI | 26.46 (4.77), 26.17 | 26.4 (4.44), 26.27 | 0.929 | <0.001 |
| Waiting time (in days) | 201.33 (163.04), 157 | 212.92 (249.55), 164.50 | 0.638 | <0.001 |
| Ischaemia time (in minutes)† | 539.63 (251.37), 507 | 528.78 (174.43), 534 | 0.677 | 0.001 |
| Follow-up | 1,315 (805.32), 1,332 | 1,200 (752.15), 1,318 | 0.26 | 0.004 |
| Primary non-function∗ | 3 (1.27%) | 6 (6%) | – | – |
| Graft loss∗ | 18 (7.63%) | 5 (5%) | – | – |
| Death∗ | 56 (23.73%) | 25 (25%) | – | – |
| Cause of death | 0.71 | 0.093 | ||
| Graft†† | 2 (3.6%) | 2 (8%) | ||
| Organ failure# | 9 (16.07%) | 5 (20%) | ||
| Recurrence of the initial liver disease | 8 (14.29%) | 4 (16%) | ||
| Cancer‡ | 11 (19.64%) | 5 (20%) | ||
| Infections | 9 (16.07%) | 2 (8%) | ||
| Cardiovascular | 5 (8.93%) | 0 (0%) | ||
| Non-infectious complications¶ | 1 (1.79%) | 0 (0%) | ||
| Other | 11 (19.64%) | 7 (28%) | ||
| DQI group at risk | 0.116 | 0.08 | ||
| 0 | 57 (24.15%) | 34 (34%) | ||
| 1 | 113 (47.88%) | 46 (46%) | ||
| 2 | 66 (27.97%) | 20 (20%) | ||
| Donor height | 166.75 (10.02), 166 | 168.86 (12.8), 170 | 0.042 | 0.012 |
| DQI | 2 (0.49), 2 | 1.85 (0.51), 1.76 | <0.01 | 0.021 |
For quantitative covariates, the results are shown as a mean (SD), median, and for qualitative covariates as number (percentage). Student's t test, the Wilcoxon-Mann-Whitney test and the χ2 test or Fisher's exact test were used when appropriate. For each test, an ES was also reported. For χ2 and Fisher's exact tests, was calculated (i.e. magnitude of the ES; small 0.1≤ES<0.3; medium 0.3≤ES<0.5 and large ES>0.5), and for the Student's t and Wilcoxon-Mann-Whitney tests, r2 and Cohen's r2 were determined (i.e. magnitude of the ES; small 0.01≤ES<0.09; medium 0.09≤ES<0.25 and large ES>0.25), respectively. †Ischaemia time was calculated in 234 G1CA. ∗See Cox model in the Results section. ††Primary non-functioning graft; Hyperacute rejection; Acute rejection; Vascular complications; Biliary complications; Haemorrhage; other causes. #Mainly multiple organ failure (93%). ‡Hepatocellular carcinoma: 4/11 and 2/5, respectively. ¶Haemorrhage (100%).
DQI, donor quality index; ES, effect size; ICU, intensive care unit; MELD, model for end-stage liver disease.